Valuation: TELES

Market Cap 2.12M 2.43M 1.95M 1.81M 3.44M 231M 3.5M 23.43M 9.08M 113M 9.11M 8.91M 390M P/E 2024
-4.29x
P/E 2025 -
Enterprise Value 2.1M 2.4M 1.93M 1.8M 3.41M 229M 3.46M 23.19M 8.99M 112M 9.01M 8.82M 386M EV / Sales 2024
16.7x
EV / Sales 2025 7.69x
Free-Float
26.91%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 31/12/2023
Director TitleAgeSince
Chairman - -
Director/Board Member - 11/08/2019
Director/Board Member - 11/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.43M
+0.26%-0.90%-11.18%+18.91% 214B
+1.36%-7.62%-2.36%+14.44% 178B
+1.12%-4.24%-19.21%+25.65% 138B
-0.53%-2.65%+31.96%+20.54% 77.14B
0.00%+1.25%-5.31%-14.66% 73.96B
+0.46%+0.23%-22.00%+14.74% 69.64B
-0.73%-1.37%+3.10%-1.64% 57.52B
+0.22%+0.90%+15.80%+76.68% 56.45B
+0.67%-6.67%+19.68%+48.29% 48.3B
Average +0.26%-2.31%+1.16%+22.55% 101.49B
Weighted average by Cap. +0.47%-2.96%-3.19%+19.99%

Financials

2024 2025
Net sales 207K 237K 190K 177K 336K 22.56M 342K 2.29M 887K 11.07M 890K 871K 38.13M 320K 366K 293K 274K 519K 34.82M 528K 3.53M 1.37M 17.08M 1.37M 1.34M 58.85M
Net income -836K -956K -767K -716K -1.36M -91.03M -1.38M -9.24M -3.58M -44.65M -3.59M -3.51M -154M -564K -645K -518K -483K -915K -61.43M -931K -6.23M -2.42M -30.13M -2.42M -2.37M -104M
Net Debt -126K -144K -115K -107K -204K -13.67M -207K -1.39M -538K -6.71M -539K -528K -23.11M -21.94K -25.1K -20.14K -18.78K -35.61K -2.39M -36.21K -243K -93.99K -1.17M -94.26K -92.21K -4.04M
Logo TELES
Arzneiwerk VIDA AG, formerly Teles AG, is a Germany-based financial holding company. The Company is active in the pharmaceutical segment, where it focuses on the growth area of Specialty Pharma in Germany and Europe. Specialty Pharma usually includes high-priced drugs for chronic, complex, or rare diseases. It focuses on six indication areas: oncology, neurology, autoimmune diseases, ophthalmology, hemophilia, and infectious diseases. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry.
Employees
-